Licensees. Any license of any Optioned Antibody and any sublicense of the rights granted under Section 3.2(b) (Development and Commercialization License and Assignment) shall be made solely pursuant to agreements (“Sublicense Agreements”) that are consistent with all relevant terms and conditions of this Agreement and to Licensees who explicitly agree in writing to comply with all applicable terms of this Agreement, including Section 9.3 (Commitments Regarding Program-Benefited Antibodies) hereof. [***].
Appears in 2 contracts
Samples: Collaboration Agreement (Leap Therapeutics, Inc.), Collaboration Agreement (Leap Therapeutics, Inc.)
Licensees. Any license of any Optioned Antibody and any sublicense of the rights granted under Section 3.2(b3.2(b)(ii) (Development and Commercialization License and AssignmentLicense) shall be made solely pursuant to agreements (“Sublicense Agreements”) that are consistent with all relevant terms and conditions of this Agreement and to Licensees who explicitly agree in writing to comply with all applicable terms of this Agreementterms, including Section 9.3 (Commitments Regarding Program-Benefited Antibodies) hereof. [***].
Appears in 2 contracts
Samples: Sublicense Agreement (CASI Pharmaceuticals, Inc.), License Agreement (CASI Pharmaceuticals, Inc.)
Licensees. Any license of any Optioned Antibody and any sublicense of the rights granted under Section 3.2(b) (Development and Commercialization License and Assignment) shall be made solely pursuant to agreements (“Sublicense Agreements”) that are consistent with all relevant terms and conditions of this Agreement and to Licensees who explicitly agree in writing to comply with all applicable terms of this Agreement, including Section 9.3 (Commitments Regarding Program-Benefited Antibodies) hereof. [***]Checkpoint shall remain responsible for all payments and other performance obligations due under this Agreement, notwithstanding any license or sublicense that it may grant.
Appears in 1 contract
Samples: Collaboration Agreement (Checkpoint Therapeutics, Inc.)
Licensees. Any license of any Optioned Antibody and any sublicense of the rights granted under Section 3.2(b) (Development and Commercialization License and Assignment) shall be made solely pursuant to agreements (collectively, “Sublicense Licensee Agreements”) that are consistent with all relevant terms and conditions of this Agreement and to Licensees who explicitly agree in writing to comply with all applicable terms of this Agreement, including Section 9.3 9.4 (Commitments Regarding Program-Benefited Antibodies) hereof. [***].
Appears in 1 contract
